1. Home
  2. QCLS vs BOLD Comparison

QCLS vs BOLD Comparison

Compare QCLS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QCLS

Q/C Technologies Inc.

SELL

Current Price

$4.03

Market Cap

31.1M

Sector

Health Care

ML Signal

SELL

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.42

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
QCLS
BOLD
Founded
2014
2018
Country
United States
United States
Employees
2
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.1M
36.5M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
QCLS
BOLD
Price
$4.03
$1.42
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
396.5K
63.3K
Earning Date
04-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.96
52 Week High
$8.17
$1.68

Technical Indicators

Market Signals
Indicator
QCLS
BOLD
Relative Strength Index (RSI) 51.86 50.23
Support Level $3.86 $1.40
Resistance Level $4.66 $1.53
Average True Range (ATR) 0.28 0.05
MACD -0.00 -0.00
Stochastic Oscillator 53.68 38.46

Price Performance

Historical Comparison
QCLS
BOLD

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: